Regenicin, Inc. Stock Other OTC
Equities
RGIN
US75887Q1022
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | - | Sales 2022 | - | Capitalization | 491K |
---|---|---|---|---|---|
Net income 2021 | - | Net income 2022 | - | EV / Sales 2021 | - |
Net Debt 2021 | 598K | Net Debt 2022 | 627K | EV / Sales 2022 | - |
P/E ratio 2021 |
-2
x | P/E ratio 2022 |
-0.71
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 79.1% |
Managers | Title | Age | Since |
---|---|---|---|
Randall McCoy
CEO | Chief Executive Officer | 74 | 10-07-14 |
John Weber
DFI | Director of Finance/CFO | 74 | 10-09-12 |
J. Nelson
CTO | Chief Tech/Sci/R&D Officer | 75 | 10-07-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Weber
DFI | Director of Finance/CFO | 74 | 10-09-12 |
Randall McCoy
CEO | Chief Executive Officer | 74 | 10-07-14 |
1st Jan change | Capi. | |
---|---|---|
+9.15% | 105B | |
-1.08% | 104B | |
+5.79% | 22.94B | |
-11.55% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.91% | 16.96B | |
+7.55% | 14.16B | |
+40.04% | 12.63B |